André Andonian, Flagship chair of Asia Pacific and senior advisor
November 7, 2023 05:00 PM ESTUpdated November 11, 01:48 AM
Financing
Startups
Bioregnum

Flag­ship Pi­o­neer­ing takes an­oth­er big step across the globe, plant­i­ng its biotech flag in Asia

Flag­ship Pi­o­neer­ing is stak­ing out a new home base in Asia, re­cruit­ing a long­time McK­in­sey vet — and a col­league to Flag­ship CEO Noubar Afeyan — to start work­ing on a fresh set of strate­gic deals in the re­gion for its port­fo­lio of biotechs. The move to tap An­dré An­don­ian for the role of Sin­ga­pore chair comes af­ter a move in­to Lon­don ear­li­er in the year un­der­scored Flag­ship’s am­bi­tions out­side the US.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE
ENDPOINTS CAREERS

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

J&J show­cas­es more blad­der can­cer re­sults from 'pret­zel' drug-de­vice com­bo

Phar­ma com­pa­nies soft­en tone on full IRA im­pact

Lon­nel Coats an­nounces re­tire­ment from Lex­i­con; An­oth­er shake­up in Vir's C-suite

sponsored

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

A service from the Financial Times